Amylin analogs

Novel amylin analogs with specific amino acid sequences address the limitations of existing amylin therapies by enhancing stability and reducing side effects, offering improved glucose control and weight management for metabolic disorders.

WO2025160082A9 Publication Date: 2026-06-18VIKING THERAPEUTICS INC
0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
VIKING THERAPEUTICS INC
Filing Date
2025-01-21
Publication Date
2026-06-18

AI Technical Summary

⚠Technical Problem

Existing amylin analogs, such as pramlintide, have limitations including short half-life, frequent dosing requirements, gastrointestinal side effects, and limited efficacy for weight loss and glucose control, making them unsuitable for treating metabolic disorders like obesity and diabetes.

⚗Method used

Development of novel amylin analogs with specific amino acid sequences, such as Formula (I), which include lipidated isoglutamic acid and disulfide bridges, to enhance stability and reduce side effects, allowing for improved glucose control and weight management.

🎯Benefits of technology

The novel amylin analogs provide extended half-life, reduced side effects, and enhanced efficacy in treating metabolic disorders, including obesity and diabetes, without the limitations of existing therapies.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The present invention encompasses polypeptides of Formula (I), and pharmaceutically acceptable salts thereof that are effective as amylin analogs. Amylin analogs of Formula (I) find use in the treatment of metabolic disorders or metabolic syndrome in a subject.
Need to check novelty before this filing date? Find Prior Art